Market Intelligence, Clinical Progress, and High-Purity Reagents for Vasomotor Symptoms and Endocrine Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TACR3 (Neurokinin 3 Receptor) drug discovery. Because TACR3 is a complex 7-transmembrane GPCR, preserving its native conformation is paramount. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Primary Focus) | TACR3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. High Titer, Sequence Verified. |
View TACR3 Products |
| Antigen | TACR3 Full-Length Membrane Protein / Peptides HEK293 expressed, Detergent-solubilized preparation, >95% purity. Sequence Verified. Endotoxin <1EU/ug. |
View TACR3 Products |
| Validator | TACR3 siRNA Set (3 unique sequences) For knockdown verification in calcium flux assays. Endotoxin controlled. |
View TACR3 Products |
| Related Target A (NK1R) | TACR1 Subfamily selectivity screening (avoid Substance P cross-reactivity); synergistic for dual-antagonist development (e.g., Elinzanetant). |
View TACR1 Products |
| Related Target B (NK2R) | TACR2 Subfamily selectivity screening (avoid Neurokinin A cross-reactivity). |
View TACR2 Products |
| Related Target C (KNDy) | KISS1R Upstream KNDy neuron pathway regulator for reproductive health. |
View KISS1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity | Lentivirus-mediated stable expression in HEK293; preserves native glycosylation and Gq/11 coupling efficiency required for functional calcium flux. |
| Calcium Flux Signal Consistency | High-titer lentivirus (>10^8 TU/ml) ensures uniform receptor density for FLIPR/FLUO-8 assays with Z' > 0.8. |
| Subfamily Selectivity (vs NK1/NK2) | Human TACR1, TACR2, and TACR3 lentiviral panels available for high-throughput selectivity assays; ortholog proteins with sequence-verified identity for cross-screening. |
| Species Cross-Reactivity | Human/Mouse/Cyno ortholog ORFs available with absolute sequence fidelity for in vivo model translation. |
| False Positive Binding | Validated siRNA included for specific knockdown controls in binding and functional assays. |
Live TACR3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for TACR3 (NK3R) has undergone a historic breakthrough with the FDA approval of Astellas's Fezolinetant (Veozah) in May 2023, establishing non-hormonal TACR3 antagonism as the new gold standard for menopausal vasomotor symptoms (VMS). The market is rapidly expanding beyond single-target therapies. A major secondary wave is being driven by dual TACR1/TACR3 antagonists (e.g., Bayer's Elinzanetant, Phase 3) aiming to address broader symptom clusters, including sleep disturbances, while minimizing off-target metabolic effects. Future pipeline expansions are increasingly focused on Polycystic Ovary Syndrome (PCOS), endometriosis, and sex hormone-related endocrine modulation. Additionally, exploratory research investigates TACR3 signaling in prostate and breast oncology contexts, leveraging the receptor's role in the KNDy neuron axis for thermoregulation.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Antagonist) | Astellas Pharma | Vasomotor Symptoms (VMS) | Functional Ca²⁺ Assay (Need robust stable cell lines via Lentivirus) |
| Small Molecule (Dual Antagonist) | Bayer | VMS, Sleep Disturbances | Selectivity Profiling (Need strictly validated TACR1/TACR3 panel) |
| Combination Therapy | Myovant, Research Institutions | Hormone-sensitive Cancers | Receptor Occupancy Assay (Need high-purity membrane preparations) |
| Biased Ligands | Academic Labs | CNS/Peripheral discrimination | Pathway Selectivity Panel (Need Gq/11 vs Beta-arrestin bias assays) |
| Small Molecule / Peptides | Emerging Biotechs | PCOS, Endocrine Disorders | Ortholog Screening (Need Mouse/Cyno sequences for in vivo models) |